By Aidan Sowa, CEO and Founder, Frontier Industries | October 2026
The first powered surgical tools reached operating rooms more than a century ago, and surgeons trusted them because a colleague had used one and lived to describe it. That is still how your device gets adopted, except the colleague now publishes, posts and appears in a regulator database before your sales team hears about it. This guide applies one test to every agency you interview: could this team protect your name on the worst day of your product's life, not just promote it on the best one. Most cannot, and the difference shows up in the recall file.
| Measure | Figure | Source |
|---|---|---|
| Device recall events, fiscal 2020 to 2024 | 3,934 | GAO analysis of FDA data, 2025 |
| Share of those recalls still listed as ongoing at review | 62 percent | GAO, 2025 |
| Device industry annual output in the United States | More than 250 billion dollars | AdvaMed, 2025 |
I. Discrimen
Clearance is a regulatory event, not a reputation
A 510(k) clearance or a PMA approval means the FDA found your device acceptable for a defined set of indications. It says nothing about whether a hospital value analysis committee trusts your company, whether a surgeon will attach her name to your launch, or whether a journalist believes your safety story. Buyers inside hospitals read your regulatory file and your public record as one document.
Agencies that blur this line will pitch you launch coverage built on claims your clearance does not support. That is not enthusiasm. It is a compliance failure with a byline. Your first screening question is therefore simple: ask the agency to walk you through the last claim they talked a healthcare client out of making. A team that has never refused a claim has never read one closely.
A clearance letter opens a market. It does not open a single operating room.
II. Machina
Your reputation is assembled from databases before it is assembled from stories
The machinery of device reputation runs on public records. The FDA recall database, MAUDE adverse event reports, warning letters and the agency's own early alert postings are read daily by trade reporters, hospital risk managers and your competitors. When the Government Accountability Office reviewed device recalls initiated from fiscal 2020 through 2024 (GAO, 2025), it counted 3,934 events, and Class I recalls, the most serious category, made up about 9 percent of them.
Your agency does not control this machinery. It can only decide whether your company's voice arrives inside it early, accurately and in plain language, or late and lawyered into fog. The practical test in any pitch meeting: ask how the team monitors FDA postings, how fast they can draft a holding statement, and who on the team has actually written one. Vague answers here predict vague performance in a crisis.
Reporters do not discover your recall. Your regulator publishes it, and reporters grade your response.
The same machinery runs in peacetime, only slower. Clearance summaries, 510(k) databases and adverse event reports shape what a diligence team believes about you long before a sales meeting is booked. Hospitals building a case for or against your product will pull your MAUDE history, count your corrections and read the tone of every field action you have filed. A good agency treats those public records as an editorial surface: monitoring them weekly, flagging patterns your quality team should see, and making sure your own announcements never contradict what the database already says about you. When your press release celebrates a flawless safety record that your adverse event file quietly disputes, you have not bought publicity. You have bought an exhibit.
III. Exemplum
Infusion pumps show what the two kinds of response look like
Consider one device family. An analysis of FDA recall records for infusion pumps counted 584 classified recall events, of which 189, roughly one in three, were Class I (MedDeviceGuide, 2026). Pumps are ordinary, essential and unforgiving of software and alarm faults, which is exactly why the category is instructive. Every pump maker faces the same database. What differs is the communication wrapped around it.
The stronger pattern, visible in FDA's own early alert pilot launched in November 2024, is speed plus specificity: the GAO account describes an issue where the agency informed the public three days after the manufacturer alerted providers (GAO, 2025). The weaker pattern is the correction notice written to be unread, heavy on reassurance and light on lot numbers, affected models and instructions. Clinicians notice the difference, and they keep their own files.
In a recall, the correction notice is the brand. Everything else was advertising.
IV. Damnum
A slow recall story costs more than the recall
The financial damage of a device problem rarely ends when the engineering fix ships. The GAO found that 62 percent of the recalls it reviewed were still listed as ongoing at the time of its analysis, and that closing a recall took an average of about 260 business days against an FDA goal of 90 (GAO, 2025). For most of a year, sometimes longer, anyone searching your product finds an open file.
That open file is where your agency earns its fee. Procurement teams check it before contract renewals. Plaintiff firms cite it. Recruiters lose candidates to it. Meanwhile the cause pattern is unglamorous: FDA officials told a 2024 industry conference that the top root causes of Class I recalls were process control, device design and nonconforming material (RAPS, 2024), and devices accumulated 32,336 recalls across fiscal 2012 to 2024, more than food, drugs or biologics (RAPS, 2024). Your communications partner must be able to explain manufacturing language without flinching.
An unresolved recall is a homepage you did not design and cannot take down.
V. Genus
The controlling variable is claim discipline
Strip away agency size, trophy clients and pitch theatre, and one variable predicts outcomes for device makers: whether the agency treats every claim as a regulatory object. Your cleared indications define what you may say. Your clinical data define what you can support. Your marketing must live inside the smaller of those two circles.
Ask each candidate agency to mark up a page of your current product copy against your indications for use. A medtech literate team will flag comparative claims, outcome promises and off label implications within minutes. A generalist team will compliment the design. The same discipline applies to safety language: the agency should know the difference between a correction, a removal and a recall, because the FDA does, and because using the soft word when the hard one applies is the fastest way to lose a trade editor for good.
Precision is not the enemy of publicity here. Precision is the price of admission.
Put the discipline in a calendar and it stops depending on individual vigilance. Strong device communicators run a standing review rhythm: every external statement about performance, safety or comparison passes a named regulatory reader before release, and the substantiation file for each live claim is reviewed whenever a study publishes, a competitor launches, or your own indications change. Claims decay. A sentence that was accurate at clearance can become false when a rival's trial reads out or when your post market data accumulates in a direction the sentence does not admit. The agency you want maintains that claim register as a living document and brings it to quarterly meetings unasked, because it understands that in this industry your archive of old sentences is either an asset or a discovery request.
VI. Regio
Segment the audience before you segment the media list
Device buyers are not one audience, and an agency that pitches them as one will waste your launch window. At minimum you are speaking to five groups, each with its own evidence standard and its own reading habits.
| Audience | What persuades them | Where they check you |
|---|---|---|
| Surgeons and proceduralists | Peer use, case data, complication honesty | Conference sessions, society journals |
| Hospital value analysis committees | Total cost, safety record, service reliability | FDA databases, peer institution references |
| Supply chain and GPO staff | Recall history, fill rates, contract stability | Vendor scorecards, recall notices |
| Patients, for home use devices | Plain language safety guidance, recall clarity | News coverage, FDA alerts, support forums |
| Investors and partners | Regulatory pathway credibility, pipeline discipline | Trade press, FDA decision summaries |
The agency you hire should present a plan per segment, not a media list with forty names and no reasoning. If their plan for the value analysis committee is the same document as their plan for surgeons, they have not sold into a hospital before.
VII. Occasio
The opening sits in safety transparency, and it is still unclaimed
Here is the gap your agency should exploit. FDA review timelines are public and often long: device news tracking of June 2024 clearances found a median of 146 days to decision across that month's 510(k) cohort (Medical Device News Update, 2024). During those months your competitors say nothing, and the trade press has space to fill. The companies that publish honestly about the process, the testing and the limits of their evidence become the category's explainers.
The same opening exists in post market life. Few manufacturers communicate proactively about complaint handling, software update discipline or field corrective action timelines. The first mid size maker in a category to do it consistently sets the standard the giants get measured against. An agency that proposes only launch moments and conference parties is leaving this territory empty for a rival to occupy.
Silence during review is a habit, not a rule. Break it carefully and it becomes an asset.
There is a second opening in reimbursement work, and it is equally underused. Coverage decisions, coding changes and hospital budget cycles all generate public documents and trade coverage, yet most device companies let consultants narrate that territory alone. The manufacturer whose agency can explain, accurately and early, why a procedure's economics work for a hospital becomes a source reporters call when payment policy shifts. That source status transfers: the company trusted to explain money gets believed about safety. Build the habit during quiet quarters, because it cannot be manufactured in the week your recall posts.
VIII. Structura
A small manufacturer with a clean record out argues a giant with a slow one
Scale impresses procurement departments less than device founders expect. The US industry is economically large, more than 250 billion dollars in annual output and nearly three million direct and indirect jobs (AdvaMed, 2025), but it is made of thousands of firms, most of them small, selling to buyers who verify everything. Verification is your equaliser. A forty person company that answers a safety question in one day, with documents, beats a multinational whose statement took three weeks and three law firms.
Test for this in selection. Give each finalist agency a mock scenario: a Class II recall in your largest product line, discovered on a Friday. Score the speed, accuracy and tone of what comes back. You are not buying creativity in that exercise. You are buying the temperament your name will wear in public.
Nobody audits your mission statement. Everybody audits your correction notices.
IX. Consilium
Hire for the recall day, then let them earn the launch days
Choose the agency in the wrong order and you get glossy launch coverage followed by an improvised crisis. Choose in the right order and the same team that wrote your holding statements writes your launch, which means the launch claims were built to survive scrutiny from the start.
| Agency option | Strength for a device maker | Watch out for |
|---|---|---|
| Medtech specialist agency | Knows FDA vocabulary, trade press and recall mechanics | Small teams can thin out during simultaneous client crises |
| Large healthcare practice inside a network agency | Deep benches, global reach for multi market launches | Your account may be staffed by generalists between pitch and delivery |
| Regulatory consultancy with a communications arm | Claim review is native, documentation is strong | Media instincts can be cautious to the point of invisibility |
| Senior independent consultant plus your in house lead | Fast, senior, inexpensive, knows your product deeply | No surge capacity when a recall and a launch land together |
| General B2B technology agency | Strong storytelling and digital craft | Will need educating on indications, adverse events and recall classes |
Score finalists against criteria that reflect your risk, not their reel.
| Criterion | Weight in your decision | Evidence to demand |
|---|---|---|
| Recall and correction experience | High | Redacted holding statements or timelines they managed |
| Regulatory claim literacy | High | A live markup of your copy against your indications |
| Trade media relationships in your specialty | Medium | Named editors and recent placements in your category |
| KOL and society conference support | Medium | Examples of surgeon facing material that passed review |
| Monitoring and response speed | High | Their FDA database monitoring routine, in writing |
| Measurement honesty | Medium | Reporting that separates coverage from committee wins |
More guidance on structuring an engagement lives on the public relations services page, and the full library of sector guides sits in the resources index. Device founders comparing notes across healthcare should also read the companion guide for diagnostics companies, where the regulatory ground shifted twice in two years.
Frequently asked questions
Do we need a specialist medtech agency, or will a strong healthcare agency do?
A strong healthcare agency can work if its device bench is real. Test it with your indications for use and a mock recall. If the team cannot discuss Class I, II and III recalls or the difference between a correction and a removal without notes, it is a pharma agency wearing a device badge.
When should a device startup hire PR relative to clearance?
Earlier than feels natural. The review window, often many months, is when your category narrative forms and when journalists learn who explains the technology honestly. Hire for positioning and KOL groundwork during review, then scale at clearance.
What should our agency do in the first 24 hours of a recall?
Confirm the facts with your regulatory lead, post clear instructions for affected users, brief customer facing staff with one approved script, and notify key accounts directly before they read it elsewhere. Speed matters, but an accurate slow hour beats a fast wrong statement every time.
Can PR help with hospital value analysis committees?
Indirectly, yes. Committees read your public record: recall history, correction quality, trade coverage and the consistency of your claims. An agency that keeps that record clean and well documented is doing committee work whether it sits in the room or not.
How do we handle claims our sales team loves but our clearance does not support?
Retire them, everywhere, including distributor material and conference slides. Your agency should run a claim audit against your indications and keep a substantiation file. One off label implication in a press quote can convert a marketing problem into a regulatory one.
What reporting should we expect from a device agency?
Monthly reporting that separates activity from effect: placements in named trade titles, KOL engagements, correction and recall communications performance, share of voice on safety topics in your category, and issues flagged before they became stories. Raw impression counts are decoration.
Should our agency manage our FDA related social posts?
They can draft, but your regulatory and quality leads approve anything touching safety, performance or indications, every time, with the approval logged. Social speed is worthless if a post becomes an exhibit.
How this guide was built
This guide rests on published regulatory and industry material rather than interviews: the Government Accountability Office review of FDA device recall oversight, FDA facing trade reporting from the Regulatory Affairs Professionals Society, AdvaMed industry data, and month by month tracking of FDA clearance and recall postings. Its limits should be stated plainly. Recall statistics describe the whole device sector, and your category may run hotter or cooler than the averages cited. Clearance timelines vary widely by product code and review division. Treat the figures as the shape of the terrain, then test every claim here against your own recall history and review experience before you sign an agency.
X. Incipe
Where Frontier Industries fits in this decision
Frontier Industries works with healthcare companies whose public record has to survive regulatory reading, and medical device manufacturers sit at the sharp end of that requirement. The practice is built for the pattern this guide describes: claim discipline before coverage, recall communication rehearsed before it is needed, and trade media relationships in the categories where your buyers actually verify you. You can read about the team on the about page and compare this guide with its sibling for health insurance companies.
If you are weighing agencies now, bring your indications for use and your worst case scenario to the first call. Start the conversation at the industry campaign page or call 401-219-4207.
Sources
1. US Government Accountability Office, Medical Device Recalls: HHS and FDA Should Address Limitations in Oversight of Recall Process, GAO-26-107619. https://www.gao.gov/assets/gao-26-107619.pdf 2. Regulatory Affairs Professionals Society, MedCon: ORA official discusses Class I recalls, RRA, QMSR, reorganization. https://www.raps.org/resource/medcon-ora-official-discusses-class-i-recalls-rra.html 3. Fierce Biotech, GAO probe finds FDA staffing shortfalls delaying medical device recall work. https://www.fiercebiotech.com/medtech/gao-probe-finds-understaffed-fda-putting-medical-device-recall-work-back-burner 4. AdvaMed, U.S. Medtech Manufacturing: Driving Innovation, Jobs, and Global Impact. https://www.advamed.org/member-center/resource-library/us-medtech-industry-manufacturing-jobs-innovation/ 5. AdvaMed, Job Creation: The Economic Impact of the Medical Technology Industry. https://www.advamed.org/medical-device-industry-facts/job-creation/ 6. AdvaMed, AdvaMed Testifies in U.S. Senate. https://www.advamed.org/industry-updates/news/advamed-testifies-in-u-s-senate/ 7. Medical Device News Update, June 2024 clearance and recall tracking. https://naveenagarwalphd.substack.com/p/medical-device-news-update-june-2024 8. Medical Device News Update, October 2024 clearance and recall tracking. https://naveenagarwalphd.substack.com/p/medical-device-news-update-october2024 9. Medical Device News Update, September 2024 clearance and recall tracking. https://naveenagarwalphd.substack.com/p/medical-device-news-update-september2024 10. MedDeviceGuide, FDA Infusion Pump Recalls: 1,180 Events and the Class I Software and Alarm Causes. https://meddeviceguide.com/blog/fda-infusion-pump-class-i-recall-root-cause-analysis-2026